{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:14:40Z","timestamp":1793420080204,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.urology.2020.07.023","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T11:29:42Z","timestamp":1595590182000},"page":"172-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Increased Bacillus Calmette-Gu\u00e9rin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non\u2013Muscle-invasive Bladder Cancer in United States Clinical Practice"],"prefix":"10.1016","volume":"145","author":[{"given":"Kyle A.","family":"Richards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yi","family":"Chuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Derleth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Zivkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika","family":"Ogale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Joel","family":"Decastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2020.07.023_bib0001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756287211431976","article-title":"Best practice in the treatment of nonmuscle invasive bladder cancer","volume":"4","author":"Anastasiadis","year":"2012","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.urology.2020.07.023_bib0002","unstructured":"Surveillance EaERP. Cancer Stat Facts: Bladder Cancer. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed May 10, 2019."},{"key":"10.1016\/j.urology.2020.07.023_bib0003","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1067\/mcn.2001.117539","article-title":"Diagnosis and management of superficial bladder cancer","volume":"25","author":"Amling","year":"2001","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.urology.2020.07.023_bib0004","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/0970-1591.166445","article-title":"Non-muscle invasive bladder cancer risk stratification","volume":"31","author":"Isharwal","year":"2015","journal-title":"Indian J Urol"},{"key":"10.1016\/j.urology.2020.07.023_bib0005","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.07.023_bib0006","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.07.023_bib0007","series-title":"NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. V1.2019","year":"2018"},{"key":"10.1016\/j.urology.2020.07.023_bib0008","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JOP.2011.000480","article-title":"Adjuvant intravesical bacillus calmette-guerin therapy and survival among elderly patients with non-muscle-invasive bladder cancer","volume":"9","author":"Spencer","year":"2013","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.urology.2020.07.023_bib0009","series-title":"SEER-Medicare: Brief Description of the SEER-Medicare Database","year":"2018"},{"key":"10.1016\/j.urology.2020.07.023_bib0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jgo.2012.12.005","article-title":"A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes","volume":"4","author":"Davidoff","year":"2013","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.urology.2020.07.023_bib0011","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urology.2020.07.023_bib0012","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urology.2020.07.023_bib0013","series-title":"SEER-Medicare: Selecting the Appropriate Comorbidity SAS Macro","year":"2019"},{"key":"10.1016\/j.urology.2020.07.023_bib0014","series-title":"National Cancer Institute Division of Cancer Control and Population Sciences. Healthcare Delivery Research Program: Comorbidity SAS Macro (2014 version)","year":"2018"},{"key":"10.1016\/j.urology.2020.07.023_bib0015","unstructured":"Chuo CY, Richards KA, Zivkovic M, et\u00a0al. Validation of an algorithm in administrative claims to identify adequate intravesical Bacillus Calmette-Gu\u00e9rin therapy in elderly patients with non\u2013muscle-invasive bladder cancer. Poster presented at: 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE 2017). August 26-30, 2017; Montreal, QC, Canada."},{"key":"10.1016\/j.urology.2020.07.023_bib0016","unstructured":"United States Department of Health and Human Services. Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment. Guidance for industry. 2018. Available at: https:\/\/www.fda.gov\/media\/101468\/download. Accessed May 15, 2020."},{"key":"10.1016\/j.urology.2020.07.023_bib0017","first-page":"133","article-title":"Development of systemic and topical drugs to treat non-muscle invasive bladder cancer","volume":"1","author":"Jarow","year":"2015","journal-title":"Bl Cancer"},{"key":"10.1016\/j.urology.2020.07.023_bib0018","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.07.023_bib0019","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.07.023_bib0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.juro.2008.04.016","article-title":"Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project","volume":"180","author":"Huang","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.07.023_bib0021","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/cncr.25007","article-title":"Patterns of care for early stage bladder cancer","volume":"116","author":"Strope","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2020.07.023_bib0022","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.euf.2018.06.018","article-title":"Manufacturing and the market: rationalizing the shortage of Bacillus Calmette-Guerin","volume":"4","author":"Bandari","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2020.07.023_bib0023","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urology.2020.07.023_bib0024","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jnci\/djp039","article-title":"Provider treatment intensity and outcomes for patients with early-stage bladder cancer","volume":"101","author":"Hollenbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2020.07.023_bib0025","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1002\/cncr.25221","article-title":"Understanding the variation in treatment intensity among patients with early stage bladder cancer","volume":"116","author":"Hollingsworth","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2020.07.023_bib0026","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/cncr.26402","article-title":"Quality of care in patients with bladder cancer: a case report?","volume":"118","author":"Chamie","year":"2012","journal-title":"Cancer"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520308840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520308840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:10:45Z","timestamp":1758766245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429520308840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":26,"alternative-id":["S0090429520308840"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2020.07.023","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased Bacillus Calmette-Gu\u00e9rin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non\u2013Muscle-invasive Bladder Cancer in United States Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2020.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}